Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 1,810 of 2,219.
    «« First « Previous 1806  1807  1808  1809  1810  1811  1812  1813  1814  Next» Last»»
    EudraCT Number: 2018-004590-27 Sponsor Protocol Number: RGH-188-203 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Plc
    Full Title: 2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
    Medical condition: Adolescent patient (13-<18 years of age) with Schizophrenia
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) HU (Prematurely Ended) DE (Trial now transitioned) PL (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005980-30 Sponsor Protocol Number: 53718678RSV2008 Start Date*: 2021-11-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-003382-38 Sponsor Protocol Number: FSNANO05012022 Start Date*: 2023-01-12
    Sponsor Name:FSNANO05012022
    Full Title: Efficacy and safety of Cerebrolysin for neurorecovery after moderate-severe traumatic brain injury
    Medical condition: Moderate-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    26.1 10022117 - Injury, poisoning and procedural complications 10060690 Traumatic brain injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004006-26 Sponsor Protocol Number: RGH-MD-20 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to...
    Medical condition: Adolescent Patients (13 to 17 years of age) with Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001785-16 Sponsor Protocol Number: 2006/3:1 Start Date*: 2006-06-15
    Sponsor Name:Karolinska universitetssjukhuset
    Full Title: Neo-adjuvant behandling av esofagus-cardia cancer inför kurativt syftande resektion. Jämförande studie mellan kemo- och radiokemobehandling.
    Medical condition: Cancer of the esophagus or gastricardia concidered to be resectable at the preoperative evaluation. The following TN stages will be enrolled: T1-3, N1, T2-3N0 and T2-3N1.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000145-24 Sponsor Protocol Number: PI2015_843_0001 Start Date*: 2015-09-21
    Sponsor Name:CHU Amiens - Picardie
    Full Title: Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery (CRPS-VITC)
    Medical condition: Algoneurodystrophy CRPS type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001665 Algoneurodystrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001217-25 Sponsor Protocol Number: 2016-001217-25 Start Date*: 2016-09-07
    Sponsor Name:Uppsala University
    Full Title: Emotion, Serotonin and Premenstrual Dysphoric Disorder (EmSeP)
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004232-37 Sponsor Protocol Number: Metylpred-01 Start Date*: 2012-11-29
    Sponsor Name:Sahlgrenska Universtitetssjukhuset/SUS
    Full Title: Prophylactic treatment with methylprednisolone may reduce the cerebral inflammatory response and reduce the severity of cognitive dysfunction after cardiac surgery
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004431-24 Sponsor Protocol Number: 67896153MSC3001 Start Date*: 2022-11-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Vers...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) SE (Completed) IT (Prematurely Ended) FR (Ongoing) BE (Completed) PL (Completed) CZ (Completed) BG (Completed) HU (Prematurely Ended) PT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001657-94 Sponsor Protocol Number: SPCG 13 Start Date*: 2006-11-16
    Sponsor Name: [...]
    1.
    2. Scandinavian Prostate Cancer Group/ P.O. Hedlund
    Full Title: Randomized adjuvant phase III trial of six cycles of docetaxel+hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiothe...
    Medical condition: Intermediate or high-risk prostate cancer treated with radical radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) IE (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003156-39 Sponsor Protocol Number: FUOGT2011-1 Start Date*: 2011-08-29
    Sponsor Name:Tampere University Hospital
    Full Title: OPEN, SINGLE-ARM, MULTICENTER, PHASE II TRIAL INVESTIGATING THE SAFETY OF BIWEEKLY CABAZITAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH A DOCETAXEL-CONTA...
    Medical condition: This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of metastatic castration resistant prostate cancer (mCRPC) previously treated with docetaxel containing regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009039-32 Sponsor Protocol Number: 6368 Start Date*: 2009-04-23
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Abciximab versus Eptifibatide versus Bivalirudin during PCI in patients with acute coronary syndromes
    Medical condition: ST elevation myocardial infarction and non ST elevation myocardial infarction/unstable angina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000920 Acute myocardial infarction, subendocardial infarction LLT
    9.1 10000891 Acute myocardial infarction LLT
    9.1 10002385 Angina pectoris unstable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003567-66 Sponsor Protocol Number: T817MAEU201 Start Date*: 2019-06-11
    Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd.
    Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer...
    Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    21.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004599-21 Sponsor Protocol Number: 081012-1 Start Date*: 2013-01-04
    Sponsor Name:TAYS/teho-osasto
    Full Title: PHARMACOKINETICS OF ENOXAPARIN IN INTENSIVE CARE PATIENTS
    Medical condition: Kriittisesti sairaita tehohoitopotilaita
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10059115 Intensive care unit syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005875-10 Sponsor Protocol Number: VGFTe-ROP-2036 Start Date*: 2022-03-10
    Sponsor Name:Regeneron Pharmaceuticals. Inc.
    Full Title: An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003561-38 Sponsor Protocol Number: APHP220729 Start Date*: 2023-08-23
    Sponsor Name:Assistance publique - Hôpitaux de Paris
    Full Title: Durvalumab/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by electroporation ablation in curative intent: French multicenter phase 2 therapeutic DUMELEP trial (DUMELEP)
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001875-35 Sponsor Protocol Number: PRODIGE71-BEVAMAINT Start Date*: 2019-11-06
    Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon
    Full Title: BEVAMAINT - A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer
    Medical condition: Unresectable metastatic colorectal cancer with measurable hepatic lesions (according to RECIST V1.1)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004250-28 Sponsor Protocol Number: Psoriasi_Risa Start Date*: 2020-09-22
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: EXPLORING THE EFFECTS OF IL-23 INHIBITION BY RISANKIZUMAB ON PSORIASIS AUTOIMMUNITY.
    Medical condition: Moderate to severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004380-40 Sponsor Protocol Number: CA209-76U Start Date*: 2020-11-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab
    Medical condition: The study population will include participants diagnosed with metastatic melanoma, advanced/metastatic urothelial carcinoma (mUC), advanced hepatocellular carcinoma (HCC) in Part 1, and metastatic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004451-37 Sponsor Protocol Number: C3731003 Start Date*: 2021-09-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Sev...
    Medical condition: hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Completed) ES (Restarted)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1806  1807  1808  1809  1810  1811  1812  1813  1814  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 21:02:17 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA